The rate of xerostomia in burning mouth syndrome: a case-control study

Author(s)

do Silva, Luciana Alvarenga ^[1] ; Tesseroli de Siqueira, Jose Tadeu ^[1] ; Teixeira, Manoel Jacobsen ^[1] ; Dowgan Tesseroli de Siqueira, Silvia Regina ^[1]

Affiliation

^[1] Univ Sao Paulo, Fac Med, Dept Neurol, Sao Paulo - Brazil

• Document type: Journal article
• Source: Arquivos de Neuro-Psiquiatria; v. 72, n. 2, p. 91-98, FEB 2014.
• Web of Science Citations: 2

Abstract

Objective: To assess the efficacy of anti-xerostomic topical medication (urea 10%) in patients with burning mouth syndrome (BMS). Method: Thirty-eight subjects diagnosed with BMS according to the International Association for the Study of Pain guidelines were randomized to either placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben, and 10% glycerol in distilled water qsp 100 g) or treatment (urea 10%) to be applied to the oral cavity 3-4 times per day for 3 months. The patients were evaluated before and after treatment with the following instruments: the EDOF-HC protocol (Orofacial Pain Clinic Hospital das Clinicas), a xerostomia questionnaire, and quantitative sensory testing. Results: There were no differences in salivary flow or gustative, olfactory, or sensory thresholds (P>0.05). Fifteen (60%) patients reported improvement with the treatments (P=0.336). Conclusion: In conclusion, there were no differences between groups, and both exhibited an association between reported improvement and salivation. (AU)

• FAPESP's process: 09/08697-5 - Evaluation of the role of xerostomia in burning mouth syndrome
• Grantee: Silvia Regina Dowgan Tesseroli de Siqueira
• Support Opportunities: Regular Research Grants